{
    "nct_id": "NCT03070951",
    "official_title": "A Phase 3, Multicentre, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Daily Oral Administration of OBE2109 Alone and in Combination With Add-back Therapy for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women",
    "inclusion_criteria": "* Premenopausal woman at screening.\n* Body Mass Index ≥ 18 kg/m2.\n* Menstrual cycles ≥ 21 days and ≤ 40 days.\n* Presence of uterine fibroids.\n* Heavy menstrual blood loss for each of the 2 menstrual periods assessed at screening using the alkaline hematin method.\n\nKey\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* The subject is pregnant or breast-feeding or is planning a pregnancy within the duration of the treatment period of the study.\n* History of uterus surgery that would interfere with the study.\n* The subject's condition is so severe that she will require surgery within 6 months regardless of the treatment provided.\n* Undiagnosed abnormal uterine bleeding.\n* Significant risk of osteoporosis or history of, or known osteoporosis or other metabolic bone disease.",
    "miscellaneous_criteria": "Key"
}